Bruker (BRKR)
Market Price (9/5/2026): $58.5 | Market Cap: $8.9 BilSector: Health Care | Industry: Health Care Equipment
Bruker (BRKR)
Market Price (9/5/2026): $58.5Market Cap: $8.9 BilSector: Health CareIndustry: Health Care Equipment
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Advanced Materials. Themes include Advanced Diagnostics, Show more. | Weak multi-year price returns2Y Excs Rtn is -49%, 3Y Excs Rtn is -82% | Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 228x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 60% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.7% Key risksBRKR key risks include [1] a high vulnerability to shifts in academic and government research funding and [2] the continuous innovation pressures and market expansion challenges inherent to its high-end equipment business model. |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, Precision Medicine, and Advanced Materials. Themes include Advanced Diagnostics, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -49%, 3Y Excs Rtn is -82% |
| Expensive valuation multiplesP/EBITPrice/EBIT or Price/(Operating Income) ratio is 228x, P/CFOPrice/(Cash Flow from Operations). CFO is cash before capital expenditures. is 47x |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 60% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -4.7% |
| Key risksBRKR key risks include [1] a high vulnerability to shifts in academic and government research funding and [2] the continuous innovation pressures and market expansion challenges inherent to its high-end equipment business model. |
Qualitative Assessment
AI Analysis | Feedback
Bruker (BRKR) stock has remained largely at the same level since 5/31/2026 because of the following key factors:
1. Mixed fiscal Q2 2026 Financial Results with Revenue Miss and Goodwill Impairment.
Bruker reported mixed financial results for fiscal Q2 2026, which ended June 30, 2026. While non-GAAP diluted earnings per share (EPS) of $0.49 surpassed the consensus estimate of $0.38, the company's revenue of $838.5 million fell short of the consensus estimate of approximately $853.6 million. Additionally, Bruker recorded a GAAP diluted loss per share of $(0.41), primarily due to significant non-cash goodwill impairment charges totaling $134.9 million. This combination of a revenue miss and a substantial GAAP loss likely offset the positive non-GAAP EPS beat, contributing to the stock's stable performance.
2. Positive Organic Bookings Growth Balanced by Softened Revenue Guidance and Shifts.
Despite the mixed quarterly revenue, Bruker Scientific Instruments (BSI) demonstrated robust organic bookings growth of 10% year-over-year in fiscal Q2 2026, achieving a book-to-bill ratio above 1.0x for the fourth consecutive quarter, signaling future revenue potential. However, the company's updated full-year fiscal 2026 revenue guidance, set at $3.54 billion to $3.57 billion, while representing 3% to 4% year-over-year growth, was slightly below analyst consensus expectations. Furthermore, approximately $20 million of previously anticipated fiscal Q3 2026 revenue was expected to shift into fiscal Q4 2026 due to semiconductor customer delivery requirements, projecting a roughly flat to slightly up organic revenue for fiscal Q3. This uncertainty regarding the timing and full-year realization of revenue tempered the positive sentiment from strong bookings.
Show more
Bruker (BRKR) stock has remained largely at the same level since 5/31/2026 because of the following key factors:
1. Mixed fiscal Q2 2026 Financial Results with Revenue Miss and Goodwill Impairment.
Bruker reported mixed financial results for fiscal Q2 2026, which ended June 30, 2026. While non-GAAP diluted earnings per share (EPS) of $0.49 surpassed the consensus estimate of $0.38, the company's revenue of $838.5 million fell short of the consensus estimate of approximately $853.6 million. Additionally, Bruker recorded a GAAP diluted loss per share of $(0.41), primarily due to significant non-cash goodwill impairment charges totaling $134.9 million. This combination of a revenue miss and a substantial GAAP loss likely offset the positive non-GAAP EPS beat, contributing to the stock's stable performance.
2. Positive Organic Bookings Growth Balanced by Softened Revenue Guidance and Shifts.
Despite the mixed quarterly revenue, Bruker Scientific Instruments (BSI) demonstrated robust organic bookings growth of 10% year-over-year in fiscal Q2 2026, achieving a book-to-bill ratio above 1.0x for the fourth consecutive quarter, signaling future revenue potential. However, the company's updated full-year fiscal 2026 revenue guidance, set at $3.54 billion to $3.57 billion, while representing 3% to 4% year-over-year growth, was slightly below analyst consensus expectations. Furthermore, approximately $20 million of previously anticipated fiscal Q3 2026 revenue was expected to shift into fiscal Q4 2026 due to semiconductor customer delivery requirements, projecting a roughly flat to slightly up organic revenue for fiscal Q3. This uncertainty regarding the timing and full-year realization of revenue tempered the positive sentiment from strong bookings.
3. Broader Macroeconomic Headwinds and Life Science Industry-Specific Challenges.
The life sciences industry continues to navigate a complex macroeconomic landscape marked by inflationary pressures, dynamic capital markets, and evolving trade, tax, and drug pricing policies. Research and Development (R&D) investments within the sector remain constrained by cautious capital deployment, an oversupply in real estate, and ongoing funding challenges, particularly impacting academic and biopharma spending. Geopolitical tensions and uncertainties, including those related to US/China transactions and tariffs, also introduce regulatory complexities and can have a "chilling effect" on deals. These external industry-wide factors likely acted as a counterbalance to company-specific positives, contributing to the stock remaining largely at the same level.
Show less
Stock Movement Drivers
Fundamental Drivers
The -0.6% change in BRKR stock from 5/31/2026 to 9/4/2026 was primarily driven by a -1.7% change in the company's P/S Multiple.| (LTM values as of) | 5312026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 58.84 | 58.50 | -0.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,458 | 3,500 | 1.2% |
| P/S Multiple | 2.6 | 2.5 | -1.7% |
| Shares Outstanding (Mil) | 152 | 152 | -0.1% |
| Cumulative Contribution | -0.6% |
Market Drivers
5/31/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BRKR | -0.6% | |
| Market (SPY) | 1.8% | 9.9% |
| Sector (XLV) | 14.7% | 12.1% |
Fundamental Drivers
The 46.2% change in BRKR stock from 2/28/2026 to 9/4/2026 was primarily driven by a 43.7% change in the company's P/S Multiple.| (LTM values as of) | 2282026 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 40.01 | 58.50 | 46.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,436 | 3,500 | 1.8% |
| P/S Multiple | 1.8 | 2.5 | 43.7% |
| Shares Outstanding (Mil) | 152 | 152 | -0.1% |
| Cumulative Contribution | 46.2% |
Market Drivers
2/28/2026 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BRKR | 46.2% | |
| Market (SPY) | 12.6% | 29.8% |
| Sector (XLV) | 7.5% | 22.9% |
Fundamental Drivers
The 73.0% change in BRKR stock from 8/31/2025 to 9/4/2026 was primarily driven by a 71.0% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 33.81 | 58.50 | 73.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 3,443 | 3,500 | 1.6% |
| P/S Multiple | 1.5 | 2.5 | 71.0% |
| Shares Outstanding (Mil) | 152 | 152 | -0.5% |
| Cumulative Contribution | 73.0% |
Market Drivers
8/31/2025 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BRKR | 73.0% | |
| Market (SPY) | 20.4% | 29.5% |
| Sector (XLV) | 26.4% | 31.6% |
Fundamental Drivers
The -9.8% change in BRKR stock from 8/31/2023 to 9/4/2026 was primarily driven by a -27.4% change in the company's P/S Multiple.| (LTM values as of) | 8312023 | 9042026 | Change |
|---|---|---|---|
| Stock Price ($) | 64.88 | 58.50 | -9.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,714 | 3,500 | 28.9% |
| P/S Multiple | 3.5 | 2.5 | -27.4% |
| Shares Outstanding (Mil) | 147 | 152 | -3.6% |
| Cumulative Contribution | -9.8% |
Market Drivers
8/31/2023 to 9/4/2026| Return | Correlation | |
|---|---|---|
| BRKR | -9.8% | |
| Market (SPY) | 77.1% | 37.2% |
| Sector (XLV) | 34.7% | 41.9% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BRKR Return | 55% | -18% | 8% | -20% | -19% | 26% | 12% |
| Peers Return | 44% | -16% | -7% | 2% | 1% | 11% | 27% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 106% |
Monthly Win Rates [3] | |||||||
| BRKR Win Rate | 92% | 58% | 50% | 50% | 25% | 56% | |
| Peers Win Rate | 82% | 42% | 47% | 45% | 47% | 51% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 56% | |
Max Drawdowns [4] | |||||||
| BRKR Max Drawdown | -18% | -42% | -35% | -49% | -53% | -40% | |
| Peers Max Drawdown | -19% | -31% | -33% | -19% | -34% | -30% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: TMO, DHR, A, WAT, RVTY. See BRKR Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 9/4/2026 (YTD)
How Low Can It Go
| Event | BRKR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.0% | -18.8% |
| % Gain to Breakeven | 45.0% | 23.1% |
| Time to Breakeven | 228 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -23.6% | -9.5% |
| % Gain to Breakeven | 30.9% | 10.5% |
| Time to Breakeven | 44 days | 24 days |
| 2023 SVB Regional Banking Crisis | ||
| % Loss | -10.9% | -6.7% |
| % Gain to Breakeven | 12.3% | 7.1% |
| Time to Breakeven | 23 days | 31 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -39.5% | -24.5% |
| % Gain to Breakeven | 65.2% | 32.4% |
| Time to Breakeven | 198 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -36.8% | -33.7% |
| % Gain to Breakeven | 58.3% | 50.9% |
| Time to Breakeven | 230 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -21.4% | -19.2% |
| % Gain to Breakeven | 27.2% | 23.8% |
| Time to Breakeven | 22 days | 105 days |
In The Past
Bruker's stock fell -31.0% during the 2025 US Tariff Shock. Such a loss loss requires a 45.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | BRKR | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -31.0% | -18.8% |
| % Gain to Breakeven | 45.0% | 23.1% |
| Time to Breakeven | 228 days | 79 days |
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -23.6% | -9.5% |
| % Gain to Breakeven | 30.9% | 10.5% |
| Time to Breakeven | 44 days | 24 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -39.5% | -24.5% |
| % Gain to Breakeven | 65.2% | 32.4% |
| Time to Breakeven | 198 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -36.8% | -33.7% |
| % Gain to Breakeven | 58.3% | 50.9% |
| Time to Breakeven | 230 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -21.4% | -19.2% |
| % Gain to Breakeven | 27.2% | 23.8% |
| Time to Breakeven | 22 days | 105 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -39.0% | -17.9% |
| % Gain to Breakeven | 63.9% | 21.8% |
| Time to Breakeven | 763 days | 123 days |
| 2010 Eurozone Sovereign Debt Crisis / Flash Crash | ||
| % Loss | -29.2% | -15.4% |
| % Gain to Breakeven | 41.2% | 18.2% |
| Time to Breakeven | 114 days | 125 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -74.7% | -53.4% |
| % Gain to Breakeven | 295.2% | 114.4% |
| Time to Breakeven | 359 days | 1085 days |
| Summer 2007 Credit Crunch | ||
| % Loss | -26.7% | -8.6% |
| % Gain to Breakeven | 36.5% | 9.5% |
| Time to Breakeven | 46 days | 47 days |
In The Past
Bruker's stock fell -31.0% during the 2025 US Tariff Shock. Such a loss loss requires a 45.0% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Bruker (BRKR)
Bruker Corporation (BRKR) is a global developer, manufacturer, and distributor of high-performance scientific instruments and analytical and diagnostic solutions. The company's core mission is to provide advanced technology that enables researchers and industries worldwide to explore and understand a vast array of materials and biological systems.
A major segment of Bruker's business is dedicated to life sciences and clinical diagnostics. This includes sophisticated mass spectrometry systems, the rapid pathogen identification platform MALDI Biotyper, molecular diagnostics kits for infectious diseases like COVID-19, and advanced optical microscopy. These tools are critical for drug discovery, biomarker identification, translational research, and rapid disease diagnosis, serving pharmaceutical and biotechnology companies, academic research institutions, and diagnostic laboratories.
Bruker also offers a comprehensive portfolio for materials science and industrial applications. This includes advanced X-ray instruments, atomic force microscopy for nanoscale analysis, and specialized analytical tools for electron microscopes. Furthermore, the company supplies superconducting materials and high-technology tools for applications such as synchrotron and beamline instrumentation. These solutions support diverse industries requiring precise material characterization, quality control, and cutting-edge scientific analysis.
```AI Analysis | Feedback
Here are 1-3 brief analogies for Bruker:
- Bruker is like a more specialized Agilent Technologies, providing advanced scientific instruments for life science research, materials analysis, and diagnostics.
- Consider Bruker the ASML of scientific research; they create the essential, cutting-edge instruments that enable breakthroughs in biology, chemistry, and advanced materials science.
AI Analysis | Feedback
- Life Science Mass Spectrometry Systems: Instruments for advanced molecular analysis and characterization in various life science applications.
- MALDI Biotyper Platform & Kits: A rapid system used for microbial identification, especially pathogens, along with accompanying diagnostic test kits.
- Molecular Diagnostics Kits: Includes DNA test strips, fluorescence-based PCR technology, and genotype/fluorotype kits for molecular diagnosis.
- SARS-CoV-2 Testing Solutions: Products like Fluorotyper-SARS-CoV-2 Plus kits for the accurate diagnosis of COVID-19 infection.
- X-ray Instruments: A diverse range of analytical tools, including handheld, portable, and mobile X-ray fluorescence spectrometry instruments.
- Atomic Force Microscopy (AFM) Instrumentation: Systems designed for high-resolution surface imaging and measurement at the nanometer scale.
- Automated Metrology & Repair Equipment: Automated systems encompassing X-ray metrology, AFM defect-detection, and photomask repair and cleaning.
- Advanced Optical Fluorescence Microscopy: High-performance instruments used for sophisticated imaging in biological and materials research.
- Superconducting Materials & Devices: Manufactures metallic low-temperature superconductors and develops devices and complex tools based on these materials.
- Synchrotron and Beamline Instrumentation: Non-superconducting high-technology tools primarily used in advanced research facilities.
AI Analysis | Feedback
Bruker (BRKR) sells primarily to other companies and institutions, not individuals. Based on the company description, its major customers can be categorized as follows:
- Life Science & Clinical Diagnostics Institutions: This category includes academic research institutions, universities, pharmaceutical companies, biotechnology companies (for drug and biomarker discovery), hospitals, clinical diagnostic laboratories, and public health organizations that utilize Bruker's life science tools, mass spectrometry platforms, pathogen identification systems, and molecular diagnostics kits.
- Materials Science & Industrial R&D: Customers in this segment include research and development departments in various industries (e.g., semiconductor, advanced materials), academic materials science departments, and industrial quality control laboratories that require advanced microscopy, X-ray instruments, and metrology solutions.
- Energy, Superconductivity & Advanced Physics Research: This group comprises specialized research laboratories, government labs, and industrial partners involved in the development and application of superconducting materials, as well as those using advanced physics research tools such as synchrotron and beamline instrumentation.
AI Analysis | Feedback
AI Analysis | Feedback
Frank H. Laukien, Ph. D. Chairman, President and Chief Executive Officer
Dr. Frank H. Laukien has served as Bruker's Chairman, President, and Chief Executive Officer since February 1991 and is the company's largest stockholder. He is the son of Günther Laukien, who founded Bruker in 1960. Frank Laukien took Bruker public in 2000. He holds a Bachelor of Science degree in physics from MIT and a Ph.D. in chemical physics from Harvard University. Dr. Laukien is also an angel investor in biotherapeutics and space exploration startups, and the executive chairman of Gauss Fusion GmbH, a nuclear fusion startup.
Gerald N. Herman Executive Vice President & Chief Financial Officer
Mr. Gerald N. Herman serves as the Executive Vice President & Chief Financial Officer of Bruker Corporation.
Mark R. Munch, Ph. D. President of Bruker Nano Group and Corporate Executive Vice President
Dr. Mark R. Munch has been President of Bruker Nano, Inc. since October 2010. In March 2021, he also took on the role of Chief Executive Officer of Acuity Spatial Genomics, a Bruker majority investment. Prior to joining Bruker Nano, Inc., Dr. Munch was Executive Vice President of Veeco Instruments Inc. from February 2008 to October 2010. He also served as a Senior Vice President of Coherent, Inc. from February 2006 to January 2008 and as President and Chief Executive Officer of Cooligy, Inc., a subsidiary of Emerson Electric, from 2004 to 2006.
Juergen Srega President, Bruker CALID Group and Bruker Daltonics Division
Mr. Juergen Srega has served as President of the Bruker CALID Group since January 2013, overseeing its global operations.
Falko Busse, Ph. D. President, Bruker BioSpin Group
Dr. Falko Busse has been President of the Bruker BioSpin Group since May 2018, responsible for the management of its global operations. He previously held positions within the Bruker BioSpin Group as Deputy President and Executive Vice President of Research and Development, Operations and Marketing. Dr. Busse holds a B.A. and a Ph.D. in Physics.
AI Analysis | Feedback
Here are the key risks to Bruker Corporation's business:
- Rapid Technological Change and Intense Competition: Bruker operates in highly specialized and technologically advanced markets for scientific instruments and diagnostic solutions. The company faces a constant threat from rapid technological obsolescence and intense competition from rivals, some of whom may possess greater financial and operational resources. Failure to continuously innovate and keep pace with emerging technologies or intense pricing pressures could lead to a loss of market share and impact profitability.
- Dependence on Research Funding and Capital Expenditure Cycles: A substantial portion of Bruker's revenue is derived from sales to academic institutions, government entities, and biopharma companies. These customers' budgets for capital-intensive scientific instruments are highly susceptible to fluctuations in government research funding, grants, and corporate research and development (R&D) spending. Reduced funding, economic downturns, or geopolitical uncertainties (such as those affecting U.S. and Chinese research funding) can significantly impact demand for Bruker's products and services.
- Supply Chain Vulnerabilities: Bruker is exposed to significant supply chain challenges, including reliance on a limited number of, and sometimes sole, suppliers for critical components, as well as broader global supply chain disruptions. These vulnerabilities can result in manufacturing inefficiencies, increased costs, production delays, and potential revenue losses if the company is unable to secure adequate supplies of required materials or components.
AI Analysis | Feedback
AI Analysis | Feedback
Bruker (symbol: BRKR) operates in several significant addressable markets for its main products and services globally.
- Mass Spectrometry: The global mass spectrometry market size was estimated at USD 6.6 billion in 2024 and is projected to reach USD 10.65 billion by 2030.
- Molecular Diagnostics: The global molecular diagnostics market size was estimated at USD 18.85 billion in 2025 and is projected to reach USD 25.59 billion by 2033. This market is particularly relevant to Bruker's rapid pathogen identification platforms, DNA test strips, PCR technology, and molecular diagnostics kits.
- Clinical Microbiology: The global clinical microbiology market size is calculated at USD 4.99 billion in 2025 and is predicted to increase to approximately USD 10.45 billion by 2035.
- Microscopy: The global microscopy market size was estimated at USD 13.52 billion in 2024 and is expected to surpass around USD 27.58 billion by 2034. This includes atomic force microscopy and advanced optical fluorescence microscopy instruments offered by Bruker.
- Industrial X-Ray Instrumentation: The global industrial X-ray market was valued at USD 3.37 billion in 2024 and is expected to reach USD 5.84 billion by 2032. Additionally, the Analytical X-Ray Instrumentation Market in North America alone was valued at USD 0.85 billion in 2024 and is projected to rise to USD 1.25 billion by 2035.
- Superconducting Materials: The global superconducting materials market size was valued at USD 1.41 billion in 2024 and is projected to reach USD 4.49 billion by 2033. Low-temperature superconducting materials, a focus for Bruker, accounted for approximately 83% of this market in 2024.
- Multi-omics: The global multiomics market size is calculated at USD 3.24 billion in 2025 and is predicted to increase to approximately USD 13.22 billion by 2035. This market is key for researchers in translational research, drug, and biomarker discovery.
AI Analysis | Feedback
Bruker (BRKR) is expected to drive future revenue growth over the next two to three years through a combination of strategic acquisitions, continuous innovation in high-growth scientific fields, and expansion into new geographic markets, alongside a projected recovery in key end markets.
-
Strategic Acquisitions and Portfolio Expansion: Bruker has strategically acquired companies such as PhenomeX (single-cell analysis), Chemspeed (lab automation), ELITechGroup (molecular diagnostics), NanoString (spatial biology), and TOFWERK AG (mass spectrometry) in 2023-2024. These acquisitions are instrumental in reshaping Bruker's platform to target high-growth areas like proteomics, spatial biology, and automated research and development workflows, facilitating cross-selling and accelerated product development.
-
Product Innovation and Launches in High-Growth Scientific Fields: The company is deepening its leadership in proteomics and spatial biology with new instruments like the timsTOF Ultra/HT/SCP and timsTOF fleX MALDI imaging, which are crucial for single-cell and spatial-omics adoption in pharmaceutical and translational pathology. Bruker is also investing in advanced structural and materials platforms, including 1.2 GHz NMR, next-generation X-ray, and atomic force microscopy (AFM) for structural biology and battery materials research. Additionally, new product launches in microbiology and molecular diagnostics are contributing to enhanced high-value offerings.
-
Geographic Market Expansion: Bruker is actively pursuing growth in international markets by establishing localized content and application laboratories in China, expanding demonstration capabilities in Europe and North America, and focusing on growth in India. These efforts aim to support regional biopharmaceutical and materials research priorities.
-
Recovery and Strengthening Demand in Key End Markets: The company anticipates a partial market recovery in 2026, particularly in advanced life science research and drug discovery tools. The biopharma end markets have already shown mid-single-digit growth, with expectations for continued strengthening demand. Furthermore, the Bruker Energy & Supercon Technologies (BEST) segment, which faced headwinds in 2025, is projected to become a tailwind in 2026, following major multiyear agreements. Growth in semiconductor metrology applications is also identified as a key driver.
AI Analysis | Feedback
Share Repurchases
- In May 2021, Bruker announced a new two-year share repurchase authorization for the purchase of up to $500 million of its common stock.
- The company's capital allocation strategy prioritizes profitable growth investments, complemented by acquisitions and share repurchases.
- Future share repurchases could be funded by net proceeds if underwriters exercise their option to purchase additional Mandatory Convertible Preferred Stock from a September 2025 offering.
Share Issuance
- As of February 20, 2026, Bruker had 152,219,250 common shares and 2,760,000 Series A mandatory convertible preferred shares outstanding as of June 30, 2025.
- In September 2025, Bruker priced a public offering of $600.0 million of 6.375% Mandatory Convertible Preferred Stock, Series A, with net proceeds estimated at approximately $582.0 million (or $669.5 million if an additional option is fully exercised), intended primarily for debt repayment.
- On May 29, 2025, Bruker Corporation's stockholders approved the 2026 Incentive Compensation Plan, authorizing up to 12 million shares for future grants.
Outbound Investments
- In 2024, Bruker expanded into adjacent markets through strategic acquisitions, most notably ELITech (molecular diagnostics), Chemspeed (lab automation), and NanoString (spatial transcriptomics), which added 10% inorganic revenue growth.
- In early October 2023, Bruker completed the acquisition of PhenomeX, subsequently renamed Bruker Cellular Analysis (BCA), a functional cell biology business.
- Early in 2023, Bruker acquired a majority stake in Biognosys, a proteomics CRO services and software provider.
Capital Expenditures
- Bruker's capital expenditures were approximately $120 million in 2021, $120 million in 2022, $120 million in 2023, $110 million in 2024, and $130 million in 2025.
- For the full year 2025, capital expenditures were forecast between $80 million and $90 million.
- In Q4 2025, Bruker Corp invested $22.6 million in capital expenditures, and its free cash flow margin was low due to capital expenditures of $90.8 million absorbing a large share of operating cash flow.
Peer Outperformance in Health Care Equipment
| Ticker | Name | Rev Growth 3Y Avg | P/E | 1Y | 3Y | 5Y | 5Y Gap |
|---|---|---|---|---|---|---|---|
| BRKR | Bruker | 9.0% | -125.1x | 97.3% | -7.5% | -34.9% | — |
| ITGR | Integer | 8.4% | 33.5x | 18.7% | 55.6% | 29.9% | +65pp |
| SYK | Stryker | 9.9% | 31.2x | -22.3% | 9.0% | 15.4% | +50pp |
| STE | Steris | 9.8% | 27.2x | -6.7% | 3.6% | 8.2% | +43pp |
| LIVN | LivaNova | 10.7% | 23.9x | 40.9% | 50.6% | -3.5% | +31pp |
| ABT | Abbott Laboratories | 5.1% | 34.8x | -16.5% | 14.3% | -7.4% | +27pp |
| Industry | Names | 1Y med | 3Y med | 5Y med | Top 3 by 5Y |
|---|---|---|---|---|---|
| Health Care Distributors | 7 | 13.9% | 96.3% | 127.8% | CAH 414% · MCK 351% · COR 179% |
| Managed Health Care | 8 | 33.2% | 1.7% | 3.3% | OSCR 77% · HQY 48% · ELV 16% |
| Health Care Services | 20 | 21.0% | 52.1% | -1.5% | HIMS 238% · RDNT 134% · DGX 68% |
| Health Care Facilities | 24 | 1.8% | 4.9% | -19.0% | THC 249% · NHC 244% · ENSG 108% |
| Health Care Equipment ← | 50 | -5.3% | -4.8% | -24.0% | POCI 10775% · UFPT 318% · GKOS 200% |
| Health Care Supplies | 12 | 32.3% | -14.4% | -35.5% | LNTH 272% · HAE 59% · MMSI 23% |
| Pharmaceuticals | 63 | -0.9% | 0.6% | -36.4% | LQDA 2406% · INDV 1148% · ETON 1022% |
| Life Sciences Tools & Services | 109 | 2.4% | -28.7% | -73.9% | SNWV 1688% · MEDP 203% · AXGN 178% |
| Biotechnology | 363 | 8.8% | -25.7% | -76.8% | BRTX 73900% · DNTH 1558% · CELZ 1486% |
| Health Care Technology | 20 | -25.0% | -56.7% | -78.6% | SPOK 68% · HSTM -2% · VEEV -13% |
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Bruker Stock 7-Day Winning Spree: Stock Climbs 38% | 05/30/2026 | |
| 6-Day Rally Sends Bruker Stock Up 28% | 05/29/2026 | |
| Bruker Earnings Notes | 12/27/2025 | |
| With Bruker Stock Surging, Have You Considered The Downside? | 10/17/2025 | |
| As BRKR Surges 10% in a Week, UTHR's Story Stands Out | 08/18/2025 | |
| How Does Bruker Stock Stack Up Against Its Peers? | 08/13/2025 | |
| Is The 26.3% Decline In Bruker (BRKR) Stock A Dip Buying Opportunity? | 08/13/2025 | |
| Better Bet Than BRKR Stock: Pay Less Than Bruker To Get More From OKE, FANG | 08/12/2025 | |
| ARTICLES | ||
| Bruker Stock Surges 38%, With A 7-Day Winning Spree | 05/30/2026 | |
| Has BRKR Stock Become A Bargain After Dropping 26%? | 08/13/2025 | |
| BRKR Stock Down -30% after 7-Day Loss Streak | 08/07/2025 | |
| BRKR Stock Down -27% after 6-Day Loss Streak | 08/06/2025 | |
| Down 21%, Is BRKR Stock A Buy Now? | 08/05/2025 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 179.26 |
| Mkt Cap | 41.4 |
| Rev LTM | 6,008 |
| Op Inc LTM | 1,009 |
| FCF LTM | 913 |
| FCF 3Y Avg | 892 |
| CFO LTM | 1,118 |
| CFO 3Y Avg | 1,148 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 5.9% |
| Rev Chg 3Y Avg | 2.5% |
| Rev Chg Q | 6.8% |
| QoQ Delta Rev Chg LTM | 1.6% |
| Op Inc Chg LTM | 1.2% |
| Op Inc Chg 3Y Avg | -1.7% |
| Op Mgn LTM | 15.3% |
| Op Mgn 3Y Avg | 19.0% |
| QoQ Delta Op Mgn LTM | 0.4% |
| CFO/Rev LTM | 20.5% |
| CFO/Rev 3Y Avg | 20.1% |
| FCF/Rev LTM | 16.5% |
| FCF/Rev 3Y Avg | 16.7% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 41.4 |
| P/S | 5.4 |
| P/Op Inc | 31.0 |
| P/EBIT | 36.7 |
| P/E | 34.6 |
| P/CFO | 25.9 |
| Total Yield | 2.6% |
| Dividend Yield | 0.3% |
| FCF Yield 3Y Avg | 3.4% |
| D/E | 0.2 |
| Net D/E | 0.2 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | 6.6% |
| 3M Rtn | 12.5% |
| 6M Rtn | 33.5% |
| 12M Rtn | 31.2% |
| 3Y Rtn | 15.1% |
| 1M Excs Rtn | 6.2% |
| 3M Excs Rtn | 7.9% |
| 6M Excs Rtn | 19.0% |
| 12M Excs Rtn | 12.5% |
| 3Y Excs Rtn | -60.3% |
Comparison Analyses
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Bruker Scientific Instruments (BSI) Chemicals, Applied Markets,Life Science,In Vitro Diagnostics, | 1,210 | 1,094 | 960 | 822 | 820 |
| Bruker Scientific Instrument (BSI) NANO | 1,084 | 1,098 | 942 | 787 | 698 |
| Bruker Scientific Instruments (BSI) BioSpin | 879 | 906 | 798 | 697 | 691 |
| Bruker Energy & Supercon Technologies (BEST) | 271 | 283 | 281 | 237 | 224 |
| Intersegment revenue | -8 | -14 | -17 | -12 | -14 |
| Total | 3,437 | 3,366 | 2,964 | 2,531 | 2,418 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Bruker Scientific Instruments (BSI) Chemicals, Applied Markets,Life Science,In Vitro Diagnostics, | 263 | 246 | 232 | 216 | 227 |
| Bruker Scientific Instruments (BSI) BioSpin | 156 | 217 | 211 | 188 | 158 |
| Bruker Scientific Instrument (BSI) NANO | 101 | 124 | 158 | 138 | 73 |
| Bruker Energy & Supercon Technologies (BEST) | 27 | 35 | 32 | 30 | 22 |
| Corporate, eliminations and other | -114 | -104 | -88 | -67 | -68 |
| Unallocated expenses | -365 | -265 | -109 | -73 | |
| Total | 68 | 253 | 437 | 433 | 413 |
| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Bruker Scientific Instruments (BSI) BioSpin, Bruker Scientific Instruments (BSI) Chemicals, Applied | 6,094 | 5,648 | 4,111 | 3,508 | |
| Bruker Energy & Supercon Technologies (BEST) | 192 | 200 | 186 | 111 | 98 |
| Eliminations and other | -45 | -42 | -47 | ||
| Corporate, eliminations and other | -8 | -8 | |||
| Bruker Scientific Instruments Life Science, Bruker Scientific Instrument(BSI) NANO &Corporate | 3,560 | ||||
| Total | 6,241 | 5,807 | 4,250 | 3,612 | 3,650 |
Price Behavior
| Market Price | $58.50 | |
| Market Cap ($ Bil) | 8.9 | |
| First Trading Date | 08/04/2000 | |
| Distance from 52W High | -9.1% | |
| 50 Days | 200 Days | |
| DMA Price | $58.74 | $47.97 |
| DMA Trend | up | up |
| Distance from DMA | -0.4% | 22.0% |
| 3M | 1YR | |
| Volatility | 65.1% | 56.0% |
| Downside Capture | 92.81 | 126.50 |
| Upside Capture | 91.59 | 179.68 |
| Correlation (SPY) | 14.1% | 31.1% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -3.65 | -0.53 | 0.38 | 1.31 | 1.30 | 1.18 |
| Up Beta | -9.34 | -3.84 | -1.61 | 0.58 | 1.03 | 1.15 |
| Down Beta | 1.23 | 0.02 | 2.06 | 1.96 | 1.22 | 1.13 |
| Up Capture | -147% | 29% | 31% | 186% | 217% | 114% |
| Bmk +ve Days | 10 | 21 | 32 | 68 | 138 | 427 |
| Stock +ve Days | 11 | 19 | 29 | 59 | 123 | 361 |
| Down Capture | -60% | 84% | 45% | 106% | 115% | 107% |
| Bmk -ve Days | 11 | 21 | 32 | 59 | 113 | 324 |
| Stock -ve Days | 10 | 23 | 35 | 67 | 127 | 387 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BRKR | |
|---|---|---|---|---|
| BRKR | 97.9% | 56.0% | 1.42 | - |
| Sector ETF (XLV) | 26.5% | 16.0% | 1.28 | 31.5% |
| Equity (SPY) | 19.7% | 12.8% | 1.13 | 30.9% |
| Gold (GLD) | 24.6% | 29.2% | 0.75 | 19.9% |
| Commodities (DBC) | 44.1% | 20.4% | 1.69 | -7.2% |
| Real Estate (VNQ) | 9.1% | 13.6% | 0.39 | 12.8% |
| Bitcoin (BTCUSD) | -26.9% | 43.8% | -0.59 | 9.7% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BRKR | |
|---|---|---|---|---|
| BRKR | -7.5% | 43.7% | -0.05 | - |
| Sector ETF (XLV) | 6.6% | 15.1% | 0.25 | 47.1% |
| Equity (SPY) | 12.8% | 17.2% | 0.57 | 44.2% |
| Gold (GLD) | 19.1% | 18.8% | 0.82 | 12.7% |
| Commodities (DBC) | 10.7% | 19.5% | 0.43 | 1.3% |
| Real Estate (VNQ) | 1.7% | 18.9% | -0.01 | 33.8% |
| Bitcoin (BTCUSD) | 10.6% | 52.6% | 0.38 | 17.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BRKR | |
|---|---|---|---|---|
| BRKR | 10.7% | 38.7% | 0.38 | - |
| Sector ETF (XLV) | 10.8% | 16.7% | 0.53 | 53.6% |
| Equity (SPY) | 15.3% | 17.9% | 0.72 | 52.6% |
| Gold (GLD) | 12.4% | 16.3% | 0.62 | 10.3% |
| Commodities (DBC) | 7.9% | 18.1% | 0.35 | 11.1% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.19 | 39.3% |
| Bitcoin (BTCUSD) | 64.0% | 66.2% | 1.04 | 15.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Updated 9/4/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -21.8% | -12.4% | -12.9% |
| 5/6/2026 | 11.3% | 17.7% | 57.8% |
| 2/12/2026 | -11.6% | -8.6% | -20.5% |
| 11/3/2025 | -0.6% | 2.5% | 22.9% |
| 8/4/2025 | -8.6% | -19.9% | -12.5% |
| 5/7/2025 | 3.3% | -1.8% | -4.5% |
| 2/13/2025 | -1.0% | 2.5% | -11.0% |
| 11/5/2024 | 3.4% | -4.5% | 0.3% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 11 | 12 | 13 |
| # Negative | 13 | 12 | 11 |
| Median Positive | 3.4% | 3.1% | 7.7% |
| Median Negative | -4.4% | -6.1% | -12.5% |
| Max Positive | 11.3% | 17.7% | 57.8% |
| Max Negative | -21.8% | -19.9% | -20.5% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 8/4/2026 | -21.8% | -12.4% | -12.9% |
| 5/6/2026 | 11.3% | 17.7% | 57.8% |
| 2/12/2026 | -11.6% | -8.6% | -20.5% |
| 11/3/2025 | -0.6% | 2.5% | 22.9% |
| 8/4/2025 | -8.6% | -19.9% | -12.5% |
| 5/7/2025 | 3.3% | -1.8% | -4.5% |
| 2/13/2025 | -1.0% | 2.5% | -11.0% |
| 11/5/2024 | 3.4% | -4.5% | 0.3% |
| 8/6/2024 | -2.2% | -4.9% | 1.4% |
| 5/2/2024 | -11.3% | -6.7% | -17.1% |
| 2/13/2024 | 8.8% | 14.9% | 31.2% |
| 11/2/2023 | -1.1% | 1.2% | 16.0% |
| 8/3/2023 | -4.8% | -7.4% | -7.5% |
| 5/4/2023 | 1.7% | -5.5% | -11.0% |
| 2/9/2023 | 1.3% | 5.0% | 1.1% |
| 11/3/2022 | 5.1% | 7.1% | 9.6% |
| 8/3/2022 | -7.1% | -9.2% | -17.5% |
| 5/4/2022 | 6.3% | -1.6% | 7.7% |
| 2/11/2022 | -4.4% | -5.1% | -13.9% |
| 11/1/2021 | 0.5% | 2.5% | -0.2% |
| 8/2/2021 | -2.1% | 0.4% | 7.1% |
| 5/5/2021 | 0.7% | 0.9% | 0.1% |
| 2/16/2021 | 4.5% | 3.7% | 0.6% |
| 11/2/2020 | -0.1% | 9.5% | 17.6% |
| SUMMARY STATS | |||
| # Positive | 11 | 12 | 13 |
| # Negative | 13 | 12 | 11 |
| Median Positive | 3.4% | 3.1% | 7.7% |
| Median Negative | -4.4% | -6.1% | -12.5% |
| Max Positive | 11.3% | 17.7% | 57.8% |
| Max Negative | -21.8% | -19.9% | -20.5% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/03/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| Report Date | Filing Date | Filing |
|---|---|---|
| 06/30/2026 | 08/05/2026 | 10-Q |
| 03/31/2026 | 05/07/2026 | 10-Q |
| 12/31/2025 | 02/27/2026 | 10-K |
| 09/30/2025 | 11/05/2025 | 10-Q |
| 06/30/2025 | 08/06/2025 | 10-Q |
| 03/31/2025 | 05/07/2025 | 10-Q |
| 12/31/2024 | 03/03/2025 | 10-K |
| 09/30/2024 | 11/07/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 05/10/2024 | 10-Q |
| 12/31/2023 | 02/29/2024 | 10-K |
| 09/30/2023 | 11/09/2023 | 10-Q |
| 06/30/2023 | 08/09/2023 | 10-Q |
| 03/31/2023 | 05/10/2023 | 10-Q |
| 12/31/2022 | 03/01/2023 | 10-K |
| 09/30/2022 | 11/04/2022 | 10-Q |
| 06/30/2022 | 08/05/2022 | 10-Q |
| 03/31/2022 | 05/06/2022 | 10-Q |
| 12/31/2021 | 02/28/2022 | 10-K |
| 09/30/2021 | 11/05/2021 | 10-Q |
| 06/30/2021 | 08/05/2021 | 10-Q |
| 03/31/2021 | 05/10/2021 | 10-Q |
| 12/31/2020 | 03/01/2021 | 10-K |
| 09/30/2020 | 11/06/2020 | 10-Q |
| 06/30/2020 | 08/07/2020 | 10-Q |
| 03/31/2020 | 05/11/2020 | 10-Q |
| 12/31/2019 | 03/27/2020 | 10-K |
| 09/30/2019 | 11/04/2019 | 10-Q |
Recent Forward Guidance
Updated 8/5/2026Latest: Q2 2026 Earnings Reported 8/4/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 3.54 Bil | 3.56 Bil | 3.57 Bil | -0.8% | Lowered | Guidance: 3.58 Bil for 2026 | |
| 2026 Revenue Growth | Reported | 3.0% | 3.5% | 4.0% | -1.0% | Lowered | Guidance: 4.5% for 2026 | |
| 2026 Organic Revenue Growth | Reported | 1.0% | 1.5% | 2.0% | 0 | Affirmed | Guidance: 1.5% for 2026 | |
| 2026 Non-GAAP EPS | Reported | 2.1 | 2.12 | 2.15 | 0 | Affirmed | Guidance: 2.12 for 2026 | |
| 2026 Non-GAAP EPS Growth | Reported | 15.0% | 16.0% | 17.0% | 0 | Affirmed | Guidance: 16.0% for 2026 | |
Prior: Q1 2026 Earnings Reported 5/6/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 3.57 Bil | 3.58 Bil | 3.60 Bil | 0 | Affirmed | Guidance: 3.58 Bil for 2026 | |
| 2026 Revenue Growth | Reported | 4.0% | 4.5% | 5.0% | 0 | Affirmed | Guidance: 4.5% for 2026 | |
| 2026 Organic Revenue Growth | Reported | 1.0% | 1.5% | 2.0% | 0 | Affirmed | Guidance: 1.5% for 2026 | |
| 2026 Non-GAAP EPS | Reported | 2.1 | 2.12 | 2.15 | 0 | Affirmed | Guidance: 2.12 for 2026 | |
| 2026 EPS Growth | Reported | 15.0% | 16.0% | 17.0% | 0 | Affirmed | Guidance: 16.0% for 2026 | |
Q4 2025 Earnings Reported 2/12/2026
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | Reported | 3.57 Bil | 3.58 Bil | 3.60 Bil | 4.7% | Higher New | Actual: 3.42 Bil for 2025 | |
| 2026 Revenue Growth | Reported | 4.0% | 4.5% | 5.0% | 3.0% | Higher New | Actual: 1.5% for 2025 | |
| 2026 Organic Revenue Growth | Reported | 1.0% | 1.5% | 2.0% | 6.0% | Higher New | Actual: -4.5% for 2025 | |
| 2026 Non-GAAP EPS | Reported | 2.1 | 2.12 | 2.15 | 13.3% | Higher New | Actual: 1.88 for 2025 | |
| 2026 Non-GAAP EPS Growth | Reported | 15.0% | 16.0% | 17.0% | ||||
Q3 2025 Earnings Reported 11/3/2025
| Forward Guidance | Guidance Change | |||||||
|---|---|---|---|---|---|---|---|---|
| Metric | Source | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | Reported | 3.41 Bil | 3.42 Bil | 3.44 Bil | -1.2% | Lowered | Guidance: 3.46 Bil for 2025 | |
| 2025 Reported Revenue Growth | Reported | 1.0% | 1.5% | 2.0% | ||||
| 2025 Organic Revenue Growth | Reported | -5.0% | -4.5% | -4.0% | ||||
| 2025 Non-GAAP EPS | Reported | 1.85 | 1.88 | 1.9 | -6.2% | Lowered | Guidance: 2 for 2025 | |
Insider Activity
Updated 8/18/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pusch, Wolfgang | President BMID Group | Direct | Sell | 8182026 | 56.90 | 3,473 | 197,614 | 557,677 | Form |
| 2 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 8182026 | 57.60 | 2,000 | 115,200 | 7,104,787 | Form |
| 3 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 7162026 | 60.25 | 2,000 | 120,500 | 7,738,691 | Form |
| 4 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 6162026 | 54.76 | 2,000 | 109,520 | 7,033,539 | Form |
| 5 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 5182026 | 43.90 | 2,000 | 87,800 | 5,638,648 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Pusch, Wolfgang | President BMID Group | Direct | Sell | 8182026 | 56.90 | 3,473 | 197,614 | 557,677 | Form |
| 2 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 8182026 | 57.60 | 2,000 | 115,200 | 7,104,787 | Form |
| 3 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 7162026 | 60.25 | 2,000 | 120,500 | 7,738,691 | Form |
| 4 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 6162026 | 54.76 | 2,000 | 109,520 | 7,033,539 | Form |
| 5 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 5182026 | 43.90 | 2,000 | 87,800 | 5,638,648 | Form |
| 6 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 4162026 | 39.90 | 2,000 | 79,800 | 5,124,876 | Form |
| 7 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 3162026 | 35.44 | 2,000 | 70,880 | 4,552,020 | Form |
| 8 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 2182026 | 36.94 | 2,000 | 73,880 | 4,744,684 | Form |
| 9 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 1162026 | 49.20 | 2,000 | 98,400 | 6,319,396 | Form |
| 10 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 1132026 | 55.00 | 7,000 | 385,000 | 7,064,365 | Form |
| 11 | Munch, Mark | EXEC VP&PRES BRUKER NANO INC. | Direct | Sell | 1062026 | 49.66 | 33,843 | 1,680,647 | 6,378,494 | Form |
| 12 | Packer, Richard A | Direct | Sell | 12022025 | 48.38 | 5,028 | 243,230 | 4,313,792 | Form | |
| 13 | Ornell, John A | Direct | Sell | 11102025 | 39.00 | 6,233 | 243,087 | 1,373,268 | Form | |
| 14 | Friend, Cynthia M | Direct | Sell | 9122025 | 32.25 | 3,535 | 113,990 | 580,946 | Form |
Investor Activity (13F)
Updated Sep 5, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
Bruker — Investor Video Playlist
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.